18:25 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the company's MAGE-A10 and MAGE-A4 SPEAR T cell therapies...
22:46 , Oct 22, 2018 |  BC Extra  |  Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) fell $3.21 (30%) to $7.55 on Monday after reporting that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
18:18 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Adaptimmune raises $100M via registered direct offering

Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $100 million through the sale of 10 million ADSs at $10 in a registered direct offering to Matrix Capital Management, New Enterprise Associates and Syncona Ltd. (LSE:SYNC). The price is...
16:28 , Sep 5, 2018 |  BC Extra  |  Financial News

Adaptimmune raises $100M via registered direct offering

Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $100 million through the sale of 10 million ADSs at $10 in a registered direct offering to Matrix Capital Management, New Enterprise Associates and Syncona Ltd. (LSE:SYNC). The price is...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
16:50 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports Phase I safety data for TCR therapy

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported safety data from eight evaluable patients receiving 90-100 million cells of its MAGE-A10 SPEAR T cell therapy in two open-label Phase I trials to treat cancer. The data were presented...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...